BridgeBio Pharma(Global Rights of NULIBRY ) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

BridgeBio Pharma(Global Rights of NULIBRY ) General Information

Description

Injection approved by U.S. Food and Drug Administration (FDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type-A, an ultra-rare, life-threatening pediatric genetic disorder.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • Palo Alto, CA
  • United States
Primary Industry
Buildings and Property
Corporate Office
  • Palo Alto, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BridgeBio Pharma(Global Rights of NULIBRY ) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BridgeBio Pharma(Global Rights of NULIBRY )‘s full profile, request access.

Request a free trial

BridgeBio Pharma(Global Rights of NULIBRY ) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BridgeBio Pharma(Global Rights of NULIBRY )‘s full profile, request access.

Request a free trial

BridgeBio Pharma(Global Rights of NULIBRY ) FAQs

  • Where is BridgeBio Pharma(Global Rights of NULIBRY ) headquartered?

    BridgeBio Pharma(Global Rights of NULIBRY ) is headquartered in Palo Alto, CA.

  • What industry is BridgeBio Pharma(Global Rights of NULIBRY ) in?

    BridgeBio Pharma(Global Rights of NULIBRY )’s primary industry is Buildings and Property.

  • Is BridgeBio Pharma(Global Rights of NULIBRY ) a private or public company?

    BridgeBio Pharma(Global Rights of NULIBRY ) is a Private company.

  • What is BridgeBio Pharma(Global Rights of NULIBRY )’s current revenue?

    The current revenue for BridgeBio Pharma(Global Rights of NULIBRY ) is .

  • Who are BridgeBio Pharma(Global Rights of NULIBRY )’s investors?

    BridgeBio Pharma has invested in BridgeBio Pharma(Global Rights of NULIBRY ).

  • When was BridgeBio Pharma(Global Rights of NULIBRY ) acquired?

    BridgeBio Pharma(Global Rights of NULIBRY ) was acquired on 04-Mar-2022.

  • Who acquired BridgeBio Pharma(Global Rights of NULIBRY )?

    BridgeBio Pharma(Global Rights of NULIBRY ) was acquired by Sentynl Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process